References
- Visseren FLJ, Mach F, Smulders YM, Carballo D, Koskinas KC, Bäck M, et al. 2021 ESC guidelines on cardiovascular disease prevention in clinical practice. Eur Heart J. 2021;42:3227–3337. DOI: 10.1093/eurheartj/ehab484
- Mach F, Baigent C, Catapano AL, Koskinas KC, Casula M, Badimon L, et al. 2019 ESC/EAS guidelines for the management of dyslipidaemias: Lipid modification to reduce cardiovascular risk. Eur Heart J. 2020;41:111–188. DOI: 10.1093/eurheartj/ehz455
- Ference BA, Ginsberg HN, Graham I, Ray KK, Packard CJ, Bruckert E, et al. Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European Atherosclerosis Society Consensus Panel. Eur Heart J. 2017;38:2459–2472. DOI: 10.1093/eurheartj/ehx144
- Wong ND, Budoff MJ, Ferdinand K, Graham IM, Michos ED, Reddy T, et al. Atherosclerotic cardiovascular disease risk assessment: An American Society for Preventive Cardiology clinical practice statement. Am J Prev Cardiol. 2022;10:
100335 . DOI: 10.1016/j.ajpc.2022.100335 - Goldstein JL, Brown MS. A century of cholesterol and coronaries: From plaques to genes to statins. Cell. 2015;161:161–172. DOI: 10.1016/j.cell.2015.01.036
- Benn M, Tybjærg-Hansen A, Stender S, Frikke-Schmidt R, Nordestgaard BG. Low-density lipoprotein cholesterol and the risk of cancer: A Mendelian randomization study. J Natl Cancer Inst. 2011;103:508–519. DOI: 10.1093/jnci/djr008
- Prospective Studies Collaboration; Lewington S, Whitlock G, Clarke R, Sherliker P, Emberson J, Halsey J, et al. Blood cholesterol and vascular mortality by age, sex, and blood pressure: A meta-analysis of individual data from 61 prospective studies with 55,000 vascular deaths. Lancet. 2007;370:1829–1839. DOI: 10.1016/S0140-6736(07)61778-4
- Ference BA, Yoo W, Alesh I, Mahajan N, Mirowska KK, Mewada A, et al. Effect of long-term exposure to lower low-density lipoprotein cholesterol beginning early in life on the risk of coronary heart disease: A Mendelian randomization analysis. J Am Coll Cardiol. 2012;60:2631–2639. DOI: 10.1016/j.jacc.2012.09.017
- Neaton JD, Blackburn H, Jacobs D, Kuller L, Lee DJ, Sherwin R, et al. Serum cholesterol level and mortality findings for men screened in the Multiple Risk Factor Intervention Trial. Multiple Risk Factor Intervention Trial Research Group. Arch Intern Med. 1992;152:1490–1500. DOI: 10.1001/archinte.1992.00400190110021
- Gordon T, Kannel WB, Castelli WP, Dawber TR. Lipoproteins, cardiovascular disease, and death. Arch Intern Med. 1981;141:1128–1131. DOI: 10.1001/archinte.1981.00340090024008
- Kashef MA, Giugliano G. Legacy effect of statins: 20-year follow up of the West of Scotland Coronary Prevention Study (WOSCOPS). Glob Cardiol Sci Pract. 2016;2016:
e201635 . DOI: 10.21542/gcsp.2016.35 - Sever PS, Chang CL, Gupta AK, Whitehouse A, Poulter NR; ASCOT Investigators. The Anglo-Scandinavian Cardiac Outcomes Trial: 11-year mortality follow-up of the lipid-lowering arm in the U.K. Eur Heart J. 2011;32:2525–2532. DOI: 10.1093/eurheartj/ehr333
- LIPID Study Group (Long-term Intervention with Pravastatin in Ischaemic Disease). Long-term effectiveness and safety of pravastatin in 9014 patients with coronary heart disease and average cholesterol concentrations: The LIPID trial follow-up. Lancet. 2002;359:1379–1387. DOI: 10.1016/S0140-6736(02)08351-4
- Noncommunicable Diseases Global Monitoring Framework: Indicator Definitions and Specifications. Available from:
https://cdn.who.int/media/docs/default-source/inaugural-who-partners-forum/gmf_indicator_definitions_version_nov2014438a791b-16d3-46f3-a398-88dee12e796b.pdf?sfvrsn=4b337764_1&download=true . Accessed 21 Jan 2026. - Gencer B, Marston NA, Im K, Cannon CP, Sever P, Keech A, et al. Efficacy and safety of lowering LDL cholesterol in older patients: A systematic review and meta-analysis of randomised controlled trials. Lancet. 2020;396:1637–1643. DOI: 10.1016/S0140-6736(20)32332-1
- Grundy SM, Stone NJ, Bailey AL, Beam C, Birtcher KK, Blumenthal RS, et al. 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA guideline on the management of blood cholesterol: A report of the American college of cardiology/American heart association task force on clinical practice guidelines. Circulation. 2019;139:e285–e350. DOI: 10.1161/CIR.0000000000000625
- Catapano AL, Graham I, De Backer G, Wiklund O, Chapman MJ, Ginsberg HN, et al. 2016 ESC/EAS guidelines for the management of dyslipidaemias. Eur Heart J. 2016;37:2999–3058. DOI: 10.1093/eurheartj/ehw272
- NCD Countdown 2030 Collaborators. NCD Countdown 2030: Efficient pathways and strategic investments to accelerate progress towards the Sustainable Development Goal target 3.4 in low-income and middle-income countries. Lancet. 2022;399:1266–1278. DOI: 10.1016/S0140-6736(21)02347-3
- Barrios V, Soronen J, Carter AM, Anastassopoulou A. Lipid management across Europe in the real-world setting: A rapid evidence review. Curr Med Res Opin. 2021;37:2049–2059. DOI: 10.1080/03007995.2021.1973396
- Kotseva K, De Backer G, De Bacquer D, Rydén L, Hoes A, Grobbee D, et al. Lifestyle and impact on cardiovascular risk factor control in coronary patients across 27 countries: Results from the European Society of Cardiology ESC-EORP EUROASPIRE V registry. Eur J Prev Cardiol. 2019;26:824–835. DOI: 10.1177/2047487318825350
- Ray KK, Molemans B, Schoonen WM, Giovas P, Bray S, Kiru G, et al. EU-wide cross-sectional observational study of lipid-modifying therapy use in secondary and primary care: The DA VINCI study. Eur J Prev Cardiol. 2021;28:1279–1289. DOI: 10.1093/eurjpc/zwaa047
- Ferrieres J, De Ferrari GM, Hermans MP, Elisaf M, Toth PP, Horack M, et al. Predictors of LDL-cholesterol target value attainment differ in acute and chronic coronary heart disease patients: Results from DYSIS II Europe. Eur J Prev Cardiol. 2018;25:1966–1976. DOI: 10.1177/2047487318806359
- Arca M, Ansell D, Averna M, Fanelli F, Gorcyca K, Iorga SR, et al. Statin utilization and lipid goal attainment in high or very-high cardiovascular risk patients: Insights from Italian general practice. Atherosclerosis. 2018;271:120–127. DOI: 10.1016/j.atherosclerosis.2018.02.024
- Petrov I, Dumitrescu A, Snejdrlova M, Zafrir B, Wożakowska-Kapłon B, Fabryova L, et al. Clinical management of high and very high risk patients with hyperlipidaemia in central and eastern Europe: An observational study. Adv Ther. 2019;36:608–620. DOI: 10.1007/s12325-019-0879-1
- Perez de Isla L, Alonso R, Watts GF, Mata N, Saltijeral Cerezo A, Muñiz O, et al. Attainment of LDL-cholesterol treatment goals in patients with familial hypercholesterolemia: 5-year SAFEHEART registry follow-up. J Am Coll Cardiol. 2016;67:1278–1285. DOI: 10.1016/j.jacc.2016.01.008
- Reiner Ž, De Backer G, Fras Z, Kotseva K, Tokgözoglu L, Wood D, et al. Lipid lowering drug therapy in patients with coronary heart disease from 24 European countries--Findings from the EUROASPIRE IV survey. Atherosclerosis. 2016;246:243–250. DOI: 10.1016/j.atherosclerosis.2016.01.018
- Ray KK, Haq I, Bilitou A, Aguiar C, Arca M, Connolly DL, et al. Evaluation of contemporary treatment of high- and very high-risk patients for the prevention of cardiovascular events in Europe – Methodology and rationale for the multinational observational SANTORINI study. Atheroscler Plus. 2021;43:24–30. DOI: 10.1016/j.athplu.2021.08.003
- Gitt AK, Lautsch D, Ferrieres J, Kastelein J, Drexel H, Horack M, et al. Low-density lipoprotein cholesterol in a global cohort of 57,885 statin-treated patients. Atherosclerosis. 2016;255:200–209. DOI: 10.1016/j.atherosclerosis.2016.09.004
- De Backer G, Jankowski P, Kotseva K, Mirrakhimov E, Reiner Z, Rydén L, et al. Management of dyslipidaemia in patients with coronary heart disease: Results from the ESC-EORP EUROASPIRE V survey in 27 countries. Atherosclerosis. 2019;285:135–146. DOI: 10.1016/j.atherosclerosis.2019.03.014
- Collins R, Reith C, Emberson J, Armitage J, Baigent C, Blackwell L, et al. Interpretation of the evidence for the efficacy and safety of statin therapy. Lancet. 2016;388:2532–2561. DOI: 10.1016/S0140-6736(16)31357-5
- Bhatt DL, Steg PG, Ohman EM, Hirsch AT, Ikeda Y, Mas J-L, et al. International prevalence, recognition, and treatment of cardiovascular risk factors in outpatients with atherothrombosis. JAMA. 2006;295:180–189. DOI: 10.1001/jama.295.2.180
- Banerjee A, Khandelwal S, Nambiar L, Saxena M, Peck V, Moniruzzaman M, et al. Health system barriers and facilitators to medication adherence for the secondary prevention of cardiovascular disease: A systematic review. Open Heart. 2016;3:
e000438 . DOI: 10.1136/openhrt-2016-000438 - Cholesterol Treatment Trialists’ (CTT) Collaboration; Baigent C, Blackwell L, Emberson J, Holland LE, Reith C, et al. Efficacy and safety of more intensive lowering of LDL cholesterol: A meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet. 2010;376:1670–1681. DOI: 10.1016/S0140-6736(10)61350-5
- Wang SV, Schneeweiss S, Berger ML, Brown J, de Vries F, Douglas I, et al. Reporting to improve reproducibility and facilitate validity assessment for healthcare database studies V1.0. Pharmacoepidemiol Drug Saf. 2017;26:1018–1032. DOI: 10.1002/pds.4295
- INE. Indicadores. Available from:
https://tabulador.ine.pt/censos2021/ . Accessed 5 Mar 2025. - WHO Collaborating Centre Drug Statistics Methodology. Guidelines ATC Classification DDD Assignment. Oslo: WHO Collaborating Centre Drug Statistics Methodology; 2022.
- Stone NJ, Robinson JG, Lichtenstein AH, Bairey Merz CN, Blum CB, Eckel RH, et al. Reprint: 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults. J Am Pharm Assoc (2003). 2013;63:2889–2934. DOI: 10.1016/j.jacc.2013.11.002
- European Association for Cardiovascular Prevention & Rehabilitation; Reiner Z, Catapano AL, De Backer G, Graham I, et al. ESC/EAS Guidelines for the management of dyslipidaemias: The Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). Eur Heart J. 2011;32:1769–1818. DOI: 10.1093/eurheartj/ehr158
- Gavina C, Araújo F, Teixeira C, Ruivo JA, Corte-Real AL, Luz-Duarte L, et al. Sex differences in LDL-C control in a primary care population: The PORTRAIT-DYS study. Atherosclerosis. 2023;384:
117148 . DOI: 10.1016/j.atherosclerosis.2023.05.017 - OMOP CDM v5.3. Available from:
https://ohdsi.github.io/CommonDataModel/cdm53.html . Accessed 4 Nov 2024. - Therneau TM. A package for survival analysis in R (survival package). Vienna: R Foundation for Statistical Computing; 2024. Available from:
https://vps.fmvz.usp.br/CRAN/web/packages/survival/survival.pdf . Accessed 4 Nov 2024. - Online T. A High-Level grammar of interactive graphics. Vega-Lite. Available from:
https://vega.github.io/vega-lite/ . Accessed 4 Nov 2024. - Karlson BW, Palmer MK, Nicholls SJ, Barter PJ, Lundman P. Effects of age, gender and statin dose on lipid levels: Results from the VOYAGER meta-analysis database. Atherosclerosis. 2017;265:54–59. DOI: 10.1016/j.atherosclerosis.2017.08.014
- Nicholls SJ, Brandrup-Wognsen G, Palmer M, Barter PJ. Meta-analysis of comparative efficacy of increasing dose of Atorvastatin versus Rosuvastatin versus Simvastatin on lowering levels of atherogenic lipids (from VOYAGER). Am J Cardiol. 2010;105:69–76. DOI: 10.1016/j.amjcard.2009.08.651
- Gavina C, Seabra-Carvalho D, Aguiar C, Anastassopoulou A, Teixeira C, Ruivo JA, et al. Characterization and LDL-C management in a cohort of high and very high cardiovascular risk patients: The PORTRAIT-DYS study. Clin Cardiol. 2024;47:
e24183 . DOI: 10.1002/clc.24183 - Ray KK, Haq I, Bilitou A, Manu MC, Burden A, Aguiar C, et al. Treatment gaps in the implementation of LDL cholesterol control among high- and very high-risk patients in Europe between 2020 and 2021: The multinational observational SANTORINI study. Lancet Reg Health Eur. 2023;29:
100624 . DOI: 10.1016/j.lanepe.2023.100624 - Ray KK, Molemans B, Schoonen WM, Giovas P, Bray S, Kiru G, et al. EU-wide cross-sectional observational study of lipid-modifying therapy use in secondary and primary care: The DA VINCI study. Eur J Prev Cardiol. 2021;28(11):1279–1289. Available from:
https://academic.oup.com/eurjpc/article/28/11/1279/5898664 . Accessed 21 Jan 2026. - Cholesterol Treatment Trialists’ Collaboration. Efficacy and safety of statin therapy in older people: A meta-analysis of individual participant data from 28 randomised controlled trials. Lancet. 2019;393:407–415. DOI: 10.1016/S0140-6736(18)31942-1
- Allen Maycock CA, Muhlestein JB, Horne BD, Carlquist JF, Bair TL, Pearson RR, et al. Statin therapy is associated with reduced mortality across all age groups of individuals with significant coronary disease, including very elderly patients. J Am Coll Cardiol. 2002;40:1777–1785. DOI: 10.1016/S0735-1097(02)02477-4
- Awad K, Mohammed M, Zaki MM, Abushouk AI, Lip GYH, Blaha MJ, et al. Association of statin use in older people primary prevention group with risk of cardiovascular events and mortality: A systematic review and meta-analysis of observational studies. BMC Med. 2021;19:
139 . DOI: 10.1186/s12916-021-02009-1 - Glynn RJ, Koenig W, Nordestgaard BG, Shepherd J, Ridker PM. Rosuvastatin for primary prevention in older persons with elevated C-reactive protein and low to average low-density lipoprotein cholesterol levels: Exploratory analysis of a randomized trial. Ann Intern Med. 2010;152:488–496, W174. DOI: 10.7326/0003-4819-152-8-201004200-00005
- Afilalo J, Duque G, Steele R, Jukema JW, de Craen AJM, Eisenberg MJ. Statins for secondary prevention in elderly patients: A hierarchical bayesian meta-analysis. J Am Coll Cardiol. 2008;51:37–45. DOI: 10.1016/j.jacc.2007.06.063
- Nanna MG, Navar AM, Wang TY, Mi X, Virani SS, Louie MJ, et al. Statin use and adverse effects among adults >75 years of age: Insights from the Patient and Provider Assessment of Lipid Management (PALM) registry. J Am Heart Assoc. 2018;7:
e008546 . DOI: 10.1161/JAHA.118.008546 - O’Keeffe AG, Petersen I, Nazareth I. Initiation rates of statin therapy for the primary prevention of cardiovascular disease: An assessment of differences between countries of the UK and between regions within England. BMJ Open. 2015;5:
e007207 . DOI: 10.1136/bmjopen-2014-007207 - Salami JA, Warraich H, Valero-Elizondo J, Spatz ES, Desai NR, Rana JS, et al. National trends in statin use and expenditures in the US adult population from 2002 to 2013: Insights from the Medical Expenditure Panel Survey. JAMA Cardiol. 2017;2:56–65. DOI: 10.1001/jamacardio.2016.4700
- Koopman C, Vaartjes I, Heintjes EM, Spiering W, van Dis I, Herings RMC, et al. Persisting gender differences and attenuating age differences in cardiovascular drug use for prevention and treatment of coronary heart disease, 1998-2010. Eur Heart J. 2013;34:3198–3205. DOI: 10.1093/eurheartj/eht368
- Menzin J, Aggarwal J, Boatman B, Yu J, Stern K, Harrison DJ, et al. Ezetimibe use and LDL-C goal achievement: A retrospective database analysis of patients with clinical atherosclerotic cardiovascular disease or probable heterozygous familial hypercholesterolemia. J Manag Care Spec Pharm. 2017;23:1270–1276. DOI: 10.18553/jmcp.2017.16414
- Kytö V, Tornio A. Ezetimibe use and mortality after myocardial infarction: A nationwide cohort study. Am J Prev Cardiol. 2024;19:
100702 . DOI: 10.1016/j.ajpc.2024.100702 - Bittner V, Deng L, Rosenson RS, Taylor B, Glasser SP, Kent ST, et al. Trends in the use of nonstatin lipid-lowering therapy among patients with coronary heart disease: A retrospective cohort study in the Medicare population 2007 to 2011. J Am Coll Cardiol. 2015;66:1864–1872. DOI: 10.1016/j.jacc.2015.08.042
- Wilmot KA, Khan A, Krishnan S, Eapen DJ, Sperling L. Statins in the elderly: A patient-focused approach. Clin Cardiol. 2015;38:56–61. DOI: 10.1002/clc.22338
- Jung HN, Kim M-J, Kim HS, Lee WJ, Min SH, Kim Y-J, et al. Age-related associations of low-density lipoprotein cholesterol and atherosclerotic cardiovascular disease: A nationwide population-based cohort study. J Am Heart Assoc. 2022;11:
e024637 . DOI: 10.1161/JAHA.121.024637 - Rachamin Y, Grischott T, Rosemann T, Meyer MR. Inferior control of low-density lipoprotein cholesterol in women is the primary sex difference in modifiable cardiovascular risk: A large-scale, cross-sectional study in primary care. Atherosclerosis. 2021;324:141–147. DOI: 10.1016/j.atherosclerosis.2021.02.024
- Kotseva K, Wood D, De Backer G, De Bacquer D, Pyörälä K, Keil U; EUROASPIRE III: A survey on the lifestyle, risk factors and use of cardioprotective drug therapies in coronary patients from 22 European countries. Eur J Cardiovasc Prev Rehabil. 2009;16:121–137. DOI: 10.1097/HJR.0b013e3283294b1d
- Kotseva K, Wood D, De Bacquer D, De Backer G, Rydén L, Jennings C, et al. EUROASPIRE IV: A European Society of Cardiology survey on the lifestyle, risk factor and therapeutic management of coronary patients from 24 European countries. Eur J Prev Cardiol. 2016;23:636–648. DOI: 10.1177/2047487315569401